Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(510)
•••
Comment by 2b7f6fabon Apr 04, 2019 11:08am
156 Views
Post# 29581977

RE:RE:RE:What's your selling price?

RE:RE:RE:What's your selling price?That's $15 billion in annual sales.  Valuation is probably +$100 billion.  MRK EV=$231 billion.  Keytruda is probably half that valuation or more.  This is why I'd love to see TLT1433 used in a lung cancer trial and soon.

Quattro74 wrote:
At some point, we will be on the nasdaq, and have those valuations, and some multiples and  hype. Depending on all of that we might have a very high SP. Then what type of buyout will we get?? Something that will make all of us very happy!

thadeush wrote: The value to Merck and Co of Ketruda by itself is projected to be $15 billion by 2024 (https://www.fool.com/investing/2019/01/13/heres-why-merck-co-surged-358-in-2018.aspx). With TLT's shares right now that would put it over $100/share. TLT has potential treatments for multiple cancers coming down the pipe. I think $5 is a bit low.



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities